ArticleACG case reports journal2025
Endoscopic Resection of an Esophageal Gastrointestinal Stromal Tumor After Neoadjuvant Treatment: A New Paradigm for Minimally Invasive Therapy?
Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a risk prediction model for piecemeal resection during endoscopic resection of gastric GISTs.Surgical endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal gastrointestinal stromal tumors (eGISTs) are rare. Current guidelines recommend surgical R0 resection. Here, we report on a patient diagnosed with a larger (>30 mm) localized GIST in the midesophagus. After interdisciplinary discussion and discussion with the patient, we initiated a neoadjuvant therapy with imatinib 400 mg. The tumor was downsized and removed uneventfully by endoscopic tunneling resection. Histopathology showed a 19 × 18 × 17 mm ypT1-R1 eGIST. After shared decision-making, the patient continues therapy with imatinib and is in remission 1 year after resection. Downsizing by neoadjuvant treatment could increase the number of endoscopically resectable eGISTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.